Pharmaceuticals
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced initial results from its U.S. phase 1 clinical trial (NCT...
2020-11-09 21:12
3907
GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ -- GenScript USA Inc., the world's
leading research reagent provider, announced today that the U.S. Food and Drug
Administration (FDA) has grantedEmergency Use Authorization (EUA)
2020-11-09 20:30
3837
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)
TAIPEI, Nov. 9, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercial...
2020-11-09 18:22
1794
Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million
SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a$21 million Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital, SCVC and a few other investors. The Series B financing will b...
2020-11-09 08:00
2200
CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients
TAIPEI and SAN DIEGO, Nov. 6, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced its clinical partner- Center for Advanced Research an...
2020-11-06 22:00
3521
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study
SEOUL, South Korea, Nov. 6, 2020 /PRNewswire/ -- On October 27, the bridging study results on Fexuprazan, developed by the Korean pharmaceutical company, Daewoong Pharmaceutical (Daewoong; CEOSengho Jeon), was published in the SCI medical journal Alimentary Pharmacology and Therapeutics (AP&T). F...
2020-11-06 22:00
2644
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
Key Highlights: * Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to appropriate patients inAustralia, New Zealand, Singapore, Malaysia and Brunei following exclusive distribution agreement * QINLOCK is already approved by the Therapeutics Good Administration (TGA)...
2020-11-06 05:30
4209
Porton Biologics Launched Gene and Cell Therapy CDMO Platform to Rank Among the Top of Pharma Solutions Platforms
SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- On November 1, the Opening Ceremony of Porton Biologics Gene and Cell Therapy CDMO Platform was held in Suzhou,China . As Porton Biologics is committed to building an end-to-end gene and cell therapy CDMO service platform, the phase I construction of th...
2020-11-05 15:35
5331
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)
SHANGHAI, Nov. 5, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, recently announced that the Center for Drug Evaluation (CDE) ...
2020-11-05 13:59
1382
Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc.
(TPEx: 6492), a clinical-stage biopharmaceutical company focused on
next-generation DNA Damage Response (DDR) therapeutics for the treatment of
cancer, today announced that it has submitted an Investigational New Drug
2020-11-02 22:00
1739
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors
MELBOURNE, Australia, Oct. 30, 2020 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of highly experienced ophthalmic industry expert,Tracy Valorie, as a new member to the company's Board of Directors. Ms Valorie is rec...
2020-10-30 20:00
1862
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon, KRX: 069620) announced on October 26 that the collaborative clinical research agreement between Daewoong and Tufts Medical Center was signed to prepare for the phase 2 clinical study of DWRX2003 (active i...
2020-10-29 21:00
2229
Yuyu Pharma Announces the Introduction of Anti-Bribery Management System to meet Global Standards
SEOUL, South Korea, Oct. 28, 2020 /PRNewswire/ -- On October 28, 2020, Yuyu Pharm (CEO Robert Wonsang Yu, KRX 000220) initiated steps to incorporate ISO 37001 Anti-bribery management system to strengthen the company's compliance system. During the introduction ceremony of ISO 37001 held at Yuyu P...
2020-10-28 21:00
1768
I-Mab Announces Upcoming Participation at November Conferences
SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences i...
2020-10-28 20:00
2716
Yiling Pharmaceutical: Revenue and Net Profit Attributable to the Parent Company for the First Three Quarters Already Exceeded the Full Year 2019
SHIJIAZHUANG, China, Oct. 28, 2020 /PRNewswire/ -- On October 27, Yiling Pharmaceutical (002603.SZ) released its 2020 third quarter report. In the first three quarters of the year, Yiling Pharmaceutical achieved the total operating revenue of6.447 billion yuan (about US$962 million), a 48.31% yea...
2020-10-28 17:04
6582
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'
SEOUL, South Korea, Oct. 27, 2020 /PRNewswire/ -- Daewoong Pharmaceutical, a South Korean pharmaceutical giant announced that its Covid-19 treatment candidate of sustained-release niclosamide (DWRX2003) also showed promising study results for a fight against the upcoming 'Twindemic' involving COV...
2020-10-27 21:00
1263
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company will present the latest preclinical dat...
2020-10-27 20:05
4617
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...
2020-10-27 10:03
3598
GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
HANGZHOU, China, Oct. 26, 2020 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension (PAH). GMA 301 is the first antibody drug for PAH treatment. In the ph...
2020-10-26 18:00
1467
111, Inc. Teams Up with Huluwa Pharmaceutical to Explore the New Domain of "Internet + pharmaceutical"
SHANGHAI, Oct. 15, 2020 /PRNewswire/ -- On September 24, 111, Inc. (NASDAQ: YI) (the "Company" or "111") and Hainan Huluwa Pharmaceutical Group Co., Ltd. (SH: 605199) ("Huluwa Pharmaceutical") signed a strategic partnership agreement in Shanghai. Mrs. LIU Jingping, Chairperson of Huluwa Pharmace...
2020-10-16 05:40
16343
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 308 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 300 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8687
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5594
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5163
